Rhea-AI Summary
NeuroMetrix, Inc. (Nasdaq: NURO) has launched a marketing initiative targeting chronic knee pain, utilizing direct-to-consumer digital marketing and outreach to healthcare providers. Approximately 25% of U.S. adults experience frequent knee pain, often treated with medications that can have serious side effects. Quell, a wearable TENS device, offers a non-invasive solution tailored for knee pain alleviation. The device has specific FDA clearance for nighttime use and tracks health metrics through a mobile app. Since its OTC availability in 2015, Quell 2.0 remains a frontrunner in TENS technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
FAQ
What is the current stock price of NeuroMetrix (NURO)?
NeuroMetrix (NURO) last closed at $4.58.
What is the market cap of NeuroMetrix (NURO)?
The market cap of NeuroMetrix (NURO) is approximately $8.9M.